search
Back to results

CoolSculpting and RF for the Submental (CRT)

Primary Purpose

Body Fat Disorder

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
The ZELTIQ System
Sponsored by
Zeltiq Aesthetics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Body Fat Disorder

Eligibility Criteria

22 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria

  • Male or female subjects ≥22 years of age and ≤65 years of age.
  • Treatment area skin fold thickness > 1cm (measured by caliper).
  • Dissatisfaction with the treatment area expressed by the subject as a rating of 0, 1 or 2 using the Subject Self Rating Scale (SSRS) as determined at Screening visit.
  • No weight change exceeding 5% of body weight in the preceding month.
  • Agreement to maintain his/her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study.
  • Subject has signed a written informed consent form

Exclusion Criteria

  • Body Mass Index ≥ 46.2 as determined at screening.
  • Excessive skin laxity in the treatment area for which reduction of subcutaneous fat may, in the opinion of the investigator, result in an unacceptable aesthetic result.
  • Prominent platysmal bands at rest which may interfere with assessment of treatment area.
  • Evidence of any cause of enlargement in the treatment area other than localized subcutaneous fat, such as swollen lymph nodes or ptotic submandibular glands.
  • Significant enlargement on the anterior neck that may prevent the proper placement of the applicator e.g. enlarged thyroid glands.
  • Treatment with dermal fillers, chemical peels, radiofrequency or laser procedures that may affect contour in the treatment area within the past 6 months.
  • Botulinum toxin, deoxycholic acid, or other aesthetic drug injections within the treatment area in the past 6 months.
  • History of facial nerve paresis or paralysis (such as Bell's palsy).
  • History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.) or implant in or adjacent to the area of intended treatment.
  • History of prior neck surgery, or prior surgery in the area of intended treatment.
  • Current infection in and adjacent to treatment area.
  • Known history of cryoglobulinemia, cold urticaria, cold agglutinin disease or paroxysmal cold hemoglobinuria.
  • Known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.
  • History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
  • Currently taking or has taken diet pills or weight control supplements within the past month.
  • Any dermatological conditions, such as scars in the location of the treatment area that may interfere with the treatment or evaluation.
  • Active implanted device such as a pacemaker, automatic implantable cardioverter/defibrillator (AICD), drug delivery system, or any other implantable electrical device.
  • Pregnant or intending to become pregnant in the next 6 months.
  • Lactating or has been lactating in the past 6 months.
  • Unable or unwilling to comply with the study requirements including remaining clean shaven for all study visits.
  • Currently enrolled in a clinical study of an unapproved investigational drug or device.
  • Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Sites / Locations

  • Innovation Research Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Fat Reduction

Arm Description

The treatments are designed to see if the fat can be reduced in the submental/submandibular area.

Outcomes

Primary Outcome Measures

Incidence of unanticipated adverse device effects (UADE). It is expected there will be zero UADE's.
The primary safety endpoint is measurement of unanticipated adverse device effects. All adverse events reported during and following the treatment will be included in the safety analysis. The frequency and proportion of subjects reporting each type of adverse event will be tabulated by relationship with the treatment and severity of the event.

Secondary Outcome Measures

Assessment of overall treatment outcome in submental and submandibular area using Subject-graded GAIS (SGAIS)
Overall improvement in the targeted area will be assessed by the subject using the GAIS at 12-weeks post-final treatment. The assessment will consist of writing the outcome as: Very much improved; much improved; improved; no change; worse; much worse; very much worse.

Full Information

First Posted
December 18, 2018
Last Updated
August 14, 2020
Sponsor
Zeltiq Aesthetics
search

1. Study Identification

Unique Protocol Identification Number
NCT03873779
Brief Title
CoolSculpting and RF for the Submental
Acronym
CRT
Official Title
A Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis Followed by Radiofrequency Treatment for Submental and Submandibular Contouring
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Unknown status
Study Start Date
December 18, 2018 (Actual)
Primary Completion Date
August 2020 (Anticipated)
Study Completion Date
November 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zeltiq Aesthetics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and efficacy of sequential use of CoolSculpting (Cryolipolysis) and radiofrequency treatment of the submental and submandibular area.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Body Fat Disorder

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Fat Reduction
Arm Type
Experimental
Arm Description
The treatments are designed to see if the fat can be reduced in the submental/submandibular area.
Intervention Type
Device
Intervention Name(s)
The ZELTIQ System
Intervention Description
The CoolSculpting machine will be used to perform the treatments.
Primary Outcome Measure Information:
Title
Incidence of unanticipated adverse device effects (UADE). It is expected there will be zero UADE's.
Description
The primary safety endpoint is measurement of unanticipated adverse device effects. All adverse events reported during and following the treatment will be included in the safety analysis. The frequency and proportion of subjects reporting each type of adverse event will be tabulated by relationship with the treatment and severity of the event.
Time Frame
12-weeks post final treatment
Secondary Outcome Measure Information:
Title
Assessment of overall treatment outcome in submental and submandibular area using Subject-graded GAIS (SGAIS)
Description
Overall improvement in the targeted area will be assessed by the subject using the GAIS at 12-weeks post-final treatment. The assessment will consist of writing the outcome as: Very much improved; much improved; improved; no change; worse; much worse; very much worse.
Time Frame
12-weeks post final treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria Male or female subjects ≥22 years of age and ≤65 years of age. Treatment area skin fold thickness > 1cm (measured by caliper). Dissatisfaction with the treatment area expressed by the subject as a rating of 0, 1 or 2 using the Subject Self Rating Scale (SSRS) as determined at Screening visit. No weight change exceeding 5% of body weight in the preceding month. Agreement to maintain his/her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study. Subject has signed a written informed consent form Exclusion Criteria Body Mass Index ≥ 46.2 as determined at screening. Excessive skin laxity in the treatment area for which reduction of subcutaneous fat may, in the opinion of the investigator, result in an unacceptable aesthetic result. Prominent platysmal bands at rest which may interfere with assessment of treatment area. Evidence of any cause of enlargement in the treatment area other than localized subcutaneous fat, such as swollen lymph nodes or ptotic submandibular glands. Significant enlargement on the anterior neck that may prevent the proper placement of the applicator e.g. enlarged thyroid glands. Treatment with dermal fillers, chemical peels, radiofrequency or laser procedures that may affect contour in the treatment area within the past 6 months. Botulinum toxin, deoxycholic acid, or other aesthetic drug injections within the treatment area in the past 6 months. History of facial nerve paresis or paralysis (such as Bell's palsy). History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.) or implant in or adjacent to the area of intended treatment. History of prior neck surgery, or prior surgery in the area of intended treatment. Current infection in and adjacent to treatment area. Known history of cryoglobulinemia, cold urticaria, cold agglutinin disease or paroxysmal cold hemoglobinuria. Known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. Currently taking or has taken diet pills or weight control supplements within the past month. Any dermatological conditions, such as scars in the location of the treatment area that may interfere with the treatment or evaluation. Active implanted device such as a pacemaker, automatic implantable cardioverter/defibrillator (AICD), drug delivery system, or any other implantable electrical device. Pregnant or intending to become pregnant in the next 6 months. Lactating or has been lactating in the past 6 months. Unable or unwilling to comply with the study requirements including remaining clean shaven for all study visits. Currently enrolled in a clinical study of an unapproved investigational drug or device. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kerrie Jiang, NP
Organizational Affiliation
Zeltiq Aesthetics
Official's Role
Study Director
Facility Information:
Facility Name
Innovation Research Center
City
Pleasanton
State/Province
California
ZIP/Postal Code
94588
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CoolSculpting and RF for the Submental

We'll reach out to this number within 24 hrs